Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) Files An 8-K

As previously disclosed by Acura Pharmaceuticals, Inc.(NASDAQ:ACUR) on the Current Report on Form 8-K filed on August 16, 2016 with the Securities and Exchange Commission, the Company received a written notification from The NASDAQ Stock Market LLC (“NASDAQ”) notifying the Company that it had failed to comply with NASDAQ Listing Rule 5550(b)(1) (the “Rule”) due to the Company’s failure to maintain a minimum of $2.5 million in stockholders’ equity (or meet the alternatives of market value of listed securities of $35 million or net income from continuing operations). 

Story continues below

On October 6, 2016, the Company received a letter from NASDAQ indicating that the Company was afforded until February 10, 2017 to regain compliance with the minimum stockholders’ equity requirement of $2.5 million, as set forth in the Rule. The letter was in response to a plan of compliance submitted by the Company on September 29, 2016 in which it requested an extension of time to comply with the Rule. The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital Market. 

If the Company fails to regain compliance by February 10, 2017, the Company’s common stock will be subject to delisting by NASDAQ.

An ad to help with our costs